Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

0R3M

Vivoryon Therapeutics Nv (0R3M)

Vivoryon Therapeutics Nv
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0R3M
DateTimeSourceHeadlineSymbolCompany
26/10/202418:30UK RegulatoryVivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024LSE:0R3MVivoryon Therapeutics Nv
12/10/202400:20UK RegulatoryVivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024LSE:0R3MVivoryon Therapeutics Nv
01/10/202415:00UK RegulatoryVivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL EventLSE:0R3MVivoryon Therapeutics Nv
12/09/202415:00UK RegulatoryVivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
06/09/202402:12UK RegulatoryVivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of AssociationLSE:0R3MVivoryon Therapeutics Nv
05/09/202415:00UK RegulatoryVivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024LSE:0R3MVivoryon Therapeutics Nv
18/07/202415:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
09/07/202415:00UK RegulatoryVivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
15/03/202417:00UK RegulatoryVivoryon Therapeutics N.V. Announces Changes to Board CompositionLSE:0R3MVivoryon Therapeutics Nv
04/03/202417:00UK RegulatoryVivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseLSE:0R3MVivoryon Therapeutics Nv
 Showing the most relevant articles for your search:LSE:0R3M